Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01812382 · ClinicalTrials.gov registry record · Phase 1
Retapamulin Microdialysis Feasibility Study
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01812382 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 3 participants.
The verdict
NCT01812382, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
This feasibility study will allow for the determination of the in vivo recovery and time of dialysis to optimize a future thorough microdialysis study. This is a single session, open label study to evaluate the feasibility of microdialysis for Retapamulin in healthy subjects. Three healthy subjects will be enrolled and complete the study procedures. Subjects will be admitted to the research unit on Day 1 and three microdialysis probes will be placed in the thigh of each subject prior to the start of the microdialysis procedure. After normal saline solution infusion for 30 minutes, a Retapamulin solution will be infused for 90 minutes. Saline perfusion will occur during the washout period. Microdialysis sampling will be done for 30 minutes (during the last 30 minutes of drug perfusion) and dialysate sample collection will continue every 30 minutes for 4 hours. The approximate duration of study including follow-up is 4 days.
Interventions
- DRUG Retapamulin Microdialysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2014-04-02 |
| Est. Completion | 2014-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01812382
The ClinicalTrials.gov registry entry for NCT01812382 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Retapamulin Microdialysis is the first listed.
NCT01812382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01812382 about?
NCT01812382 is a clinical study titled "Retapamulin Microdialysis Feasibility Study". This feasibility study will allow for the determination of the in vivo recovery and time of dialysis to optimize a future thorough microdialysis study. This is a single session, open label study to evaluate the feasibility of microdialysis for Retapamulin in healthy subjects. Three healthy subjects ...
What is the current status of trial NCT01812382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2014-04-02. Estimated completion is 2014-05-27.
What interventions are being tested in trial NCT01812382?
The interventions under investigation include: Retapamulin Microdialysis (DRUG).
Who is sponsoring clinical trial NCT01812382?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.